Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Stevanato Group to Report First Quarter 2023 Financial Results on May 4, 2023


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET).

Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 4, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the "Financial Results" page under the Company's Investor Relations section of its website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link:
http://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=4544003&linkSecurityString=514976446

Webcast: A live, listen-only webcast of the call will be available at the following link:
https://87399.choruscall.eu/links/stevanato230504.html

Dial in: Those who are unable to pre-register may dial in by calling:

       

Italy:

+39 02 802 09 11

       

United Kingdom:

+44 1 212 818004

       

United States:

+1 718 705 8796

       

United States Toll Free:

+1 855 265 6958

Replay:

The webcast will be archived for three months on the Company's Investor Relations section of its website at:
https://ir.stevanatogroup.com/financial-results.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com.


These press releases may also interest you

at 04:05
Forsta, the leading technology company in transforming the human experience (HX) across customer, employee, patient, member and consumer journeys, today announced it has expanded its portfolio of technology customers in the DACH region via the...

at 04:00
VIVE Arts has partnered with Musée d'Orsay in Paris to support a new exhibition - Van Gogh in Auvers-sur-Oise: The Final Months and the accompanying virtual reality experience La Palette de Van Gogh, the first ever by the museum....

at 04:00
The "Romania Unfolds" platform revolves around a mini-series of 6 video documentaries which uncover impactful stories of communities that have solved specific, local challenges by using accessible sustainable solutions....

at 04:00
Blattner Technologies, a global leader in Artificial Intelligence, has announced its acquisition of The Indoor Lab ? a cutting-edge lidar analytics company with AI-powered, advanced perception software and end to end data analytics. Earlier this...

at 04:00
Airbiquity®, a global leader in connected vehicle services, today announced a partnership with Tessolve, a leading hardware platform company for silicon and system productization for various market segments, including automotive, motorcycles,...

at 04:00
Visier, the globally recognized leader in people analytics and workforce solutions for people-powered business, is proud to announce its placement as a Strategic Leader in the 2023 Fosway 9-Gridtm for Cloud HR. This prestigious recognition...



News published on and distributed by: